{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-23-000014","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.815619+00:00","generated_at":"2026-06-19T22:55:11.061439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical posts first profitable quarter; Q4 revenue $137.9M (+76% YoY) and guides FY2023 $560-570M","bullets":["Q4 2022 net income $3.2M, diluted EPS $0.10, vs. loss of $2.4M in Q4 2021.","Q4 revenue $137.9M (76% YoY); U.S. revenue $134.3M (+78%), OUS revenue $3.6M (+28%).","Gross margin 83.9% in Q4, down from 85.8% due to inflation and supply chain costs.","Full year 2022 revenue $407.9M (+75% YoY); net loss $44.9M vs. $42.0M in 2021.","FY2023 revenue guidance $560-570M (37-40% growth); expects to add 52-56 new U.S. centers per quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-23-000014","json":"https://secwatch.observer/filing/0001609550-23-000014.json","markdown":"https://secwatch.observer/filing/0001609550-23-000014.md","text":"https://secwatch.observer/filing/0001609550-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000014/0001609550-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000014/insp-20230207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:55:11.061439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10a98c7bd00de518586841bc199f1d3b6f1fda91","claim":"Inspire Medical Systems, Inc. reported full year 2023 results: revenue $560 million to $570 million. Guidance initiated.","evidence_excerpt":"Inspire expects full year 2023 revenue to be in the range of $560 million to $570 million, which would represent growth of approximately 37% to 40% over full year 2022 revenue of $407.9 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000014/0001609550-23-000014-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$560 million to $570 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"3e52c8945e5721948ea753b05b39ef15aa2e69f4","claim":"Inspire Medical Systems, Inc. reported the fiscal year ended December 31, 2022 results: revenue $407.9 million, net income $44.9 million, EPS $1.60.","evidence_excerpt":"Highlights and Full Year 2023 Guidance • Generated revenue of $137.9 million in the fourth quarter of 2022, a 76% increase over the same quarter last year, and revenue of $407.9 million in full year 2022, a 75% increase over full year 2021 • Achieved gross margin of 83.9% in the fourth quarter of 2022 • Reported net income of $3.2 million and diluted net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000014/0001609550-23-000014-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$407.9 million"},{"label":"Net income","value":"$44.9 million"},{"label":"EPS","value":"$1.60"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9777079df57cceb273196beee5ab03277c2077f8","claim":"Inspire Medical Systems, Inc. reported the quarter ended December 31, 2022 results: revenue $137.9 million, net income $3.2 million, EPS $0.10.","evidence_excerpt":"Revenue was $137.9 million for the three months ended December 31, 2022, a 76% increase from $78.4 million in the corresponding period in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000014/0001609550-23-000014-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$137.9 million"},{"label":"Net income","value":"$3.2 million"},{"label":"EPS","value":"$0.10"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c38015aaa7631888b5041f7c2889fc6f734240a9","claim":"Inspire Medical Systems, Inc. updated its the quarter and fiscal year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"On February 7, 2023, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000014/0001609550-23-000014-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and fiscal year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}